<DOC>
	<DOCNO>NCT00859534</DOCNO>
	<brief_summary>Urticaria one common dermatological condition diverse clinical presentation cause . Solar urticaria ( SU ) rare subset physical urticaria , symptom induce direct exposure skin sunlight . As little 5 minute sun exposure cause flare whealing expose skin site , accompany severe itching . The wavelengths radiation cause eruption ( i.e . action spectrum ) ultraviolet visible light range . Initially describe Merklen 1904 , SU may sudden dramatic onset , rapidly disappear exposure cease . A delayed form SU also report , although extremely rare . Information pathophysiology SU limit symptom confine area body expose direct sunlight . The condition distress severely impair individual 's ability go outdoors tolerate indoor lighting . The standard therapy , i.e . oral antihistamine , partially effective may provide little worthwhile relief symptom . This pilot study propose evaluate implant contain 16mg CUV1647 prophylactic treatment patient SU . The effectiveness CUV1647 assess determine minimum urticarial dose treatment .</brief_summary>
	<brief_title>Phase II Solar Urticaria ( SU ) Pilot Study</brief_title>
	<detailed_description>When human skin expose ultraviolet radiation sun via use solarium , respond increase melanin level within epidermal melanocyte . Ultraviolet light enhances local production release alpha-melanocyte stimulate hormone ( alpha-MSH ) , result increase melanin level process know melanogenesis . Melanin , form eumelanin , photoprotective agent . The mechanism propose photoprotection include , limited , absorption scatter UV visible radiation , free radical scavenge quench UV light . There also increase evidence melanogenesis represent major antioxidant defence mechanism melanocyte , neutralise deleterious effect free radical active oxygen specie . Eumelanin act neutral density filter , unlike sunscreen , reduces wavelengths light equally photoprotection provide epidermal melanin pigmentation essentially independent wavelength . CUV1647 ( [ Nle4-D-Phe7 ] -alpha-MSH ) potent longer last analogue alpha-MSH stimulates production eumelanin skin without specific cell damage usually occur melanin production stimulate UV radiation . Urticaria one common dermatological condition diverse clinical presentation cause . Solar urticaria ( SU ) rare subset physical urticaria , symptom induce direct exposure skin sunlight . As little 5 minute sun exposure cause flare whealing expose skin site , accompany severe itching . The wavelengths radiation cause eruption ( i.e . action spectrum ) ultraviolet visible light range . Initially describe Merklen 1904 , SU may sudden dramatic onset , rapidly disappear exposure cease . A delayed form SU also report , although extremely rare . Information pathophysiology SU limit symptom confine area body expose direct sunlight . The condition distress severely impair individual 's ability go outdoors tolerate indoor lighting . The standard therapy , i.e . oral antihistamine , partially effective may provide little worthwhile relief symptom . This pilot study propose evaluate implant contain 16mg CUV1647 prophylactic treatment patient SU . The effectiveness CUV1647 assess determine minimum urticarial dose treatment .</detailed_description>
	<mesh_term>Urticaria</mesh_term>
	<criteria>Male female subject diagnosis solar urticaria ( confirm phototesting ) sufficient severity request treatment alleviate symptom . React provocation light source Aged 1870 year Fitzpatrick Skin Type I IV Written inform consent prior performance studyspecific procedure . Allergy CUV1647 polymer contain implant Any coexistent photodermatosis polymorphic light eruption ( PLE ) , discoid lupus erythematosus ( DLE ) erythropoietic porphyria ( EPP ) . Personal history melanoma , lentigo maligna multiple ( 3 ) dysplastic nevus . Current Bowen 's disease , basal cell carcinoma , squamous cell carcinoma , malignant premalignant skin lesion . Diagnosed HIV/AIDS hepatitis . Any evidence organ dysfunction deviation normal clinical laboratory determination judge clinically significant Investigator . History disorder gastrointestinal , hepatic , renal , cardiovascular , respiratory , endocrine ( include diabetes , Cushing 's syndrome , Addison 's disease , PeutzJeagher syndrome ) , neurological ( include seizure ) , haematological ( especially anaemia less 10 g/100 mL ) systemic disease judge clinically significant Investigator . Acute history drug alcohol abuse ( last 12 month ) . Major medical psychiatric illness . Patient assess suitable study opinion investigator ( e.g . noncompliance history , allergic local anaesthetic , faint give injection give blood ) . Female pregnant ( confirm positive serum Î²HCG pregnancy test prior baseline ) lactating . Females childbearing potential ( premenopausal , surgically sterile ) use adequate contraceptive measure ( i.e . oral contraceptive , diaphragm plus spermicide , intrauterine device ) . Sexually active men partner child bear potential use barrier contraception trial period three month hereafter . Participation clinical trial investigational agent within 30 day prior screen visit . Any factor may affect skin reflectance measurement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Solar Urticaria</keyword>
</DOC>